Investing.com - Adaptimmune Therapeutics (NASDAQ: ADAP) reported third quarter EPS of $-0.010, in line with the analyst estimate of $-0.010. Revenue for the quarter came in at $40.9M versus the consensus estimate of $18.57M.
Adaptimmune Therapeutics's stock price closed at $0.77. It is down -28.610% in the last 3 months and up 54.200% in the last 12 months.
Adaptimmune Therapeutics saw 0 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Adaptimmune Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Adaptimmune Therapeutics's Financial Health score is "good performance".
Check out Adaptimmune Therapeutics's recent earnings performance, and Adaptimmune Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar